What Happened

At ASCO 2026, Cardiff Oncology presented interim Phase II data for onvansertib in RAS-mutated mCRC, showing promising antitumor activity when combined with FOLFIRI and bevacizumab. Shanghai Kechow Pharma also shared Phase III results for Kolupin in BRAF V600E–mutant mCRC, demonstrating efficacy with tunlametinib plus vemurafenib.

Who Is Affected

Oncologists and healthcare providers treating metastatic colorectal cancer (mCRC) patients with RAS or BRAF mutations are directly impacted. Patients with these mutations, who represent a significant unmet need, stand to benefit from these emerging therapies.

Market Impact

• Cardiff Oncology’s onvansertib could disrupt the first-line treatment paradigm for RAS-mutant mCRC, a market with limited advancements in decades.
• Shanghai Kechow Pharma’s Kolupin offers a novel combination therapy for BRAF V600E–mutant mCRC, potentially improving progression-free survival.
• Both therapies are projected to drive significant revenue, with onvansertib expected to reach $1bn by 2032.

What to Watch

Monitor Cardiff Oncology’s Phase III trial of onvansertib 30mg plus FOLFIRI and bevacizumab for confirmatory evidence. Additionally, track Shanghai Kechow Pharma’s further developments with Kolupin, as it expands its clinical applications beyond mCRC.